Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) kindly took the time to speak with touchIMMUNOLOGY about the 52-week results from the phase 3 FORTIFY study investigating the efficacy and safety of risankizumab as a maintenance treatment in patients with Crohn’s disease.
His presentation entitled ‘EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY’ was given at UEG Week Virtual, 3-5 Oct 2021.
- The FORTIFY study builds on previous findings; what is currently known about the potential use of risankizumab in the treatment of Crohn’s disease? (0:17)
- What were the key findings of the FORTIFY maintenance study? (1:31)
- What is the potential role for maintenance therapy with risankizumab in clinical practice? (2:48)
Disclosures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare and non-financial support from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
Share this Video
Related Videos In Digestive Disorders
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!